Nightstar Therapeutics is a clinical-stage gene therapy company, focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The Company’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy.

Type
Public
HQ
London, GB
Founded
2013
Size (employees)
23 (est)-23%
Nightstar Therapeutics was founded in 2013 and is headquartered in London, GB
Report incorrect company information

Nightstar Therapeutics Office Locations

Nightstar Therapeutics has offices in London and Lexington
London, GB (HQ)
215 Euston Rd
Lexington, US
100, 81 Hartwell Ave
Show all (2)
Report incorrect company information

Nightstar Therapeutics Financials and Metrics

Nightstar Therapeutics Financials

USD

Net income (H1, 2017)

(7.7 m)

EBIT (H1, 2017)

(7.7 m)

Market capitalization (25-May-2018)

407.6 m

Closing share price (25-May-2018)

14.1

Cash (30-Jun-2017)

69.6 m
Nightstar Therapeutics's current market capitalization is $407.6 m.
Annual
USDFY, 2015FY, 2016

General and administrative expense

2.1 m2.1 m

R&D expense

7.2 m10.2 m

Operating expense total

9.3 m12.2 m

EBIT

(9.3 m)(12.2 m)
Half Year
USDH1, 2016H1, 2017

General and administrative expense

812 k1.4 m

R&D expense

5.1 m6.3 m

Operating expense total

5.9 m7.7 m

EBIT

(5.9 m)(7.7 m)
Annual
USDFY, 2015FY, 2016

Cash

10.7 m10.1 m

Prepaid Expenses

3.1 m4.1 m

Current Assets

13.8 m14.2 m

PP&E

253 k363 k
Half Year
USDH1, 2017

Cash

69.6 m

Prepaid Expenses

6.5 m

Current Assets

76.1 m

PP&E

342 k
Annual
USDFY, 2015FY, 2016

Net Income

(13.6 m)(12.2 m)

Depreciation and Amortization

40 k138 k

Accounts Payable

384 k419 k

Cash From Operating Activities

(9.7 m)(10.1 m)
Half Year
USDH1, 2016H1, 2017

Net Income

(5.9 m)(7.7 m)

Depreciation and Amortization

51 k95 k

Accounts Payable

91 k1.7 m

Cash From Operating Activities

(5.9 m)(5.7 m)
USDY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information